-
CCHIO 2024 | Dr. Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC
EGFR mutations are among the most common genetic abnormalities in non-squamous non-small cell lung cancer (NSCLC), and EGFR-TKIs have become the standard first-line treatment for advanced EGFR-mutant NSCLC. Despite significant advancements across three generations of EGFR-TKIs, resistance remains unavoidable. Post-resistance treatment options for EGFR-TKI patients, particularly those facing complex third-generation resistance mechanisms, are limited.
-
CCHIO 2024 | Dr. Dingzhi Huang: Advances in Small Cell Lung Cancer (SCLC) Treatment
At the 2024 CCHIO Lung Tumor Integrated Rehabilitation Session, Dr. Dingzhi Huang from Tianjin Medical University Cancer Institute and Hospital delivered a presentation titled “Advances in SCLC Treatment.” Below is a comprehensive summary of the key highlights.
-
CCHIO 2024 | Dr. Huaqing Wang: Exploring Bispecific Antibodies in Lung Cancer
Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has rapidly advanced in the treatment of lung cancer in recent years. However, challenges remain, such as limited efficacy with monotherapy and increased side effects with combination therapies. Multi-targeted combination therapies represent a potential avenue for advancing immunotherapy. Among them, bispecific antibodies (BsAbs), which simultaneously target two different…
-
Dr. Ting Deng: ADC Combination Strategies for Gastric Cancer – Directions and Advances | CSCO Gastric Cancer Committee Annual Meeting
From November 22 to 24, 2024, the CSCO Gastric Cancer Committee Annual Meeting convened in Beijing, gathering leading experts to discuss the latest advancements, challenges, and opportunities in gastric cancer management. Dr. Ting Deng from Tianjin Medical University Cancer Institute and Hospital delivered a keynote presentation titled “ADC Combination Strategies for Gastric Cancer: Directions and…
-
CCHIO 2024 | Dr. Xiuyi Zhi: Systematizing Popular Science Efforts to Enhance Public Knowledge, Trust, and Action in Cancer Prevention and Control
The 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) concluded on November 17, emphasizing a multidisciplinary approach to oncology. The event featured specialized sessions on integrated rehabilitation, public education, and cancer prevention, showcasing novel perspectives and techniques for comprehensive cancer care. During the conference, Oncology Frontier had the honor of interviewing Dr. Xiuyi Zhi, Chief…
-
CCHIO 2024丨Dr. Xiufeng Liu: Exploring the Clinical Potential of the “Cola Combination” from LEAP-002 to LEAP-012
The era of immunotherapy has brought new hope to advanced hepatocellular carcinoma (HCC), with various targeted-immune combination therapies emerging as potential breakthroughs. However, the journey of the “Cola Combination”—pembrolizumab combined with lenvatinib—has been marked by mixed results. In the LEAP-002 trial, the combination showed negative results in the general population but positive outcomes in the…
-
CTI 2024 | Dr. Ibrahim Yakoub-Agha Discusses the Application of Cellular Immunotherapy in Myelofibrosis
From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the fields of cell therapy and immune therapy from around the world. The conference served not only as an international platform for academic exchange but also as an…
-
Saluting Tradition, Building the Future: Prof. Han Kwang Yang Discusses the Mission and Vision of the Asian Oncology Society
On November 15, 2024, the 4th Asian Oncology Society opened grandly in Xi’an, China. Held alongside the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), this event, co-hosted by the Chinese Anti-Cancer Association and the Asian Oncology Society (AOS), was themed “Integration and Modernity.” It brought together oncology experts from across Asia to explore new…
Connecting Medical Expertise through Media